| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b698c934c4b923aa5bc9e441eb68d5d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7f5aec16d304aa66d8bedd4206b99e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92d68bb37673ca51462f47a9ca1e77b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc5b075047b8bd7e50e003b3396be201
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90feed589a3e72acc475f8c02e24c8e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec2d44dd0acf0f05abd9680fd2967e31 |
| publicationDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020233606-A1 |
| titleOfInvention |
Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| abstract |
This disclosure relates, at least in part, to a method of treatment. In one embodiment, the nmethod of treatment comprises administering to a subject in need of such treatment a first ntherapeutic agent including compound (1); or a pharmaceutically acceptable salt thereof in ncombination with a second therapeutic agent, wherein the first therapeutic agent and the nsecond therapeutic agent are administered either simultaneously or sequentially.n1/1 n100.0% n75.0% nCell viability . n50.0% nNormal Tumor n'HFF HOT116 n25.0%T MRC5 MDA-MB-231 n0.0% n0.1 1 10 100 nCompound (1) (pM) Doxerubicin nFigure 1 n125% n100% nCell viability n75% n---DMSO-3 n50% - - - - - - - - - - .n0 24 48 72 nTime from Compound (1) removal (hrs) nFigure 2 |
| priorityDate |
2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |